Milan, Italy, February 4th 2025 – CheckmAb S.r.l. announced today the successful achievement of the second
milestone in the collaboration with Boehringer Ingelheim for the development of a monoclonal antibody (mAb)
for cancer immunotherapy.
Cancer immunotherapies have delivered meaningful therapeutic options to some cancer patients, yet many
patients still do not respond to such therapies. The antibody under the licensing agreement selectively targets
tumor-infiltrating regulatory T lymphocytes (TI-Tregs) without affecting other immune cells outside of the tumor. It
offers the potential to overcome some of the limitations of current immune-checkpoint inhibitors and potentially
improve patient outcomes by activating anti-tumor immune responses without disrupting other functions of the
immune system.
The ongoing collaboration and development of this antibody underscores Boehringer Ingelheim’s commitment to
extend the benefits of immunotherapy to cancer patients still in need for better medicines.
"Reaching this milestone is a fantastic achievement and highlights the significant progress made by the teams.
This would not be possible without the excellent collaboration and working relationship that continues to build
between Boehringer Ingelheim and CheckmAb," said Renata Maria Grifantini, Chief Scientific Officer of CheckmAb.
"We look forward to continuing to work with Boehringer as they take this program forward with the ultimate goal
of developing safe and effective therapies for multiple tumor indications across patient populations."
Under the terms of the license agreement, CheckmAb will receive a milestone payment from Boehringer
Ingelheim. CheckmAb is eligible for additional research, development and commercial milestones up to EUR 240
million as well as royalties on the potential sales of any therapeutics arising from the collaboration and licenses.
This announcement follows the extension of the research collaboration under the licensing agreement announced
in March 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!